



History of the Irish Haemophilia Society




Brian O'Mahony



Beginning's 1968 - 1975

- Society founded by parents, doctors
- Letter sent to National Newspaper calling for people to contact new organisation
- 1970 - First treatment centre in Meath Hospital



Meeting May 22, 1968: “It was agreed that the aims of an association would be similar to the following”:



1. Registration of all *haemophiliacs*
2. To enlist all *sufferers*, their families and other interested persons as members
3. Medical and dental care for all haemophiliacs
4. Education of *sufferers* and their families in the handling of their problems
5. Dissemination of information concerning haemophilia
6. To give assistance in the solution of individual problems of education, job-training, psychological adjustment, rehabilitation and finances



Brian O Mahony, I H S AGM & Annual Conference 2018



Treatment outside Dublin

Mercy Hospital, Cork



Regional Hospital, Galway



1970's

- First Newsletter
- Free treatment - 1970 Health Act
- Swimming pool access
- Priority - education and extra home tuition as required
- 120 PWH on register
- First fundraiser
- Centre moved to St. James in 1977

The Irish Haemophilia Society Cumann Haemifile na hÉireann

Tel: 723

Hon. Secretary

NEWSLETTER TO MEMBERS - FEBRUARY 1970

Good wishes for 1970, when we hope that more and more members will get to know each other.

Haemophilia Treatment Centre: The Treatment Centre is now in full swing at the Meath Hospital, Dublin 8 (Tel: 52983) for adults, and National Children's Hospital, Harcourt Street, Dublin 2 (Tel: 52355) for children. Immediate admission to the centre for treatment can be arranged at any time, by having the patient's doctor phone the doctor on call for haemophiliacs at either hospital, and haemophiliacs or parents are also encouraged to suggest to their doctors that a visit to the centre for full assessment would be very valuable. An appointment to attend as an out-patient may be arranged by phoning or writing to Miss Secretary to the Haemophilia Treatment Centre, at either of the above hospitals. We will be delighted to help. Already the Centre is proving invaluable to many haemophiliacs, and all concerned hope that it will be used more and more by those who need it, no matter where they live.

Annual General Meeting: At the first annual general meeting in November, there was an encouraging attendance of over fifty, and apologies were received from many members who would have liked to attend. It was a very interesting meeting, and the general feeling was that the next meeting should be followed by some type of refreshments, as the social side of any get-together of the Society is considered welcome and useful by everybody.


Subscription: One of the decisions at the meeting was that an optional, token membership subscription of 5/- should be introduced for each individual or family. There have been some offers by members to arrange fund-raising events, and the committee is at present looking into the legal aspect of this, so that anyone good enough to be interested, will be fully informed of the position.

Informal meetings: Some members of the society have written to the Secretary asking how to get in touch with other members of similar age and interests, and if any more interested members would like to write, it might well be possible to arrange for agreeable and helpful contacts in some area around the country.

Free Medical Treatment: It is most helpful if we can have had problems. Please write to the Secretary, of course, appear in

Education: It is as our project for 1 could send the sec standing, lack of t duties, etc. We nea problem.

Please do write to with your problems





I.H.S. services in the 1970's

- Outreach to find person with haemophilia and have them register at Centre in Meath or Harcourt Street – Bill O'Sullivan and Jack Downey
 - Set the tone for the type of organisation we became
- Swimming lessons
- Christmas cards
- Paid for rental of television in hospital
- Visited members in hospital
- Treatment rudimentary- plasma/cryoprecipitate and some factor concentrates.
- Hospitalisation frequent

AGM 1982



Brian O Mahony, I H S AGM & Annual Conference 2018



The Society in 1982

- No permanent office - mail went to home address of whoever was Honorary Secretary
- No staff - all activities carried out by volunteers
- Annual “Flag day” fundraiser
- Budget was approximately £4,000 per year





page 1

11/10 - 4/12 1101 1101 1101

MINUTES OF MEETING OF THE IRISH HAEMOPHILIA SOCIETY ON THURSDAY
28th July 1983 AT THE IRISH CANCER SOCIETY ROOMS, NORTHUMBERLAND
ROAD.

IHS 2/37

Present: Phil Byrne, Chairwoman, Jack Downey, Treasurer, Sharon
Dixon, Con Curtin, Brian O'Mahoney, Shay Farrelly, Sec.

Apologies: John Scallan, Noel O'Leary. M Dunne

Minutes of the previous meeting were read and adopted.



Brian O'Mahoney asked had we received a reply from Prof.
Temperley to our letter of 31/5/1983 concerning AIDS. He
stressed his concern regarding the possible transmission
of AIDS and HEPATITIS through American blood products. He
pointed out that Germany & Switzerland had already banned
US products. He also stated that we should exert pressure
to have home produced products used.






1982 – 1987 : HIV hits the community

- Newsletters, AGM the major activities
- **AIDS hit the Community**
 - Society sponsored research into Immune system
 - Educational materials
 - Speakers at conferences
 - Worked to try to influence availability of safer treatment
 - Provision of Condoms



1988

- 9 cases of AIDS in PWH; 4 deaths
- Society supports members in Legal case
- Published:
Aids, Haemophilia and the Government – sent to Minister in May
- Called for a co-ordinated response from Government or a Trust Fund
- November- no response- decision to lobby politically and in media for recompense
- December- death toll now at 6





1989 Recompense campaign

- Society supports and funds legal test case
- Meetings with TDs/Opposition health spokespersons, Minister
- Continuing media coverage- factual and personal stories
- Private members Motion in Dail calling for fund of £400,000 annually for 3 years -results in Government defeat
- **Government calls election after Dail defeat on Haemophilia motion**
- **Haemophilia HIV Trust (HHT) established**
- Society gets first funding from Government- used to employ staff

1989 Dail defeat for Government



Private Members' Business. - HIV Infected Haemophiliacs: Motion.

Tuesday, 25 April 1989

An Ceann Comhairle: I now call Deputy Howlin. The Deputy has some 40 minutes to present his case.

Mr. Howlin:

Dáil Éireann Debate
Vol. 389 No. 1

Page 27 of 103

Charlie has them quaking

THE EARTH moves for Taoiseach Charles Haughey wherever he goes, or so it seemed at 2.15 am on Wednesday when he was awakened suddenly by a loud noise in his suite on the 14th floor of Tokyo's Imperial Hotel. The hotel was shaking as the result of the latest of the capital city's regular earthquakes.

Anxious members of the Taoiseach's party were relieved to discover that no masonry had fallen on the leader's head and that he was unruffled by the turbulence. Everyone went back to sleep in preparation for the

On his return to Dublin, the news of the Government's defeat on the Labour motion over an annual £400,000 State-funded trust for AIDS-infected haemophiliac sufferers found the Taoiseach in sabe-rattling form, so much so that he threatened a political earthquake here in the shape of a general election.

Opposition politicians are convinced that this was a show of Oriental bluster on the part of the Taoiseach, who in his absence from the country was out of touch with the mood of moral indignation, widespread among the people, that the Government has failed to meet its commitments to victims of a State-monopolised blood transfusion system. The election threat enlivened the proceedings in Sligo tomorrow when delegates to the Fianna Fáil Sligo-Leitrim selection convention choose a candidate to replace former Finance Minister Ray MacSharry, now EC Agriculture Commissioner. According to local sources, the odds appear to favour a victory for Padraic MacSharry, a brother of the Commissioner, over businessman Seamus Monaghan. As in Japan, dynastic politics still rule in Ireland — unless, of course, a political earthquake erupts in Sligo and brings Coun-





First funding from Government

13. Measures taken to date to assist infected Haemophiliacs in Ireland.
- (i) By Dept. of Health to Society
 - Grant of £5,000 in 1988 from National Lottery to Irish Haemophilia Society for support services.
 - Further grant of £50,000 offered (February 1989) but no indication from Society to date of acceptance.
 - (ii) From Eastern Health Board (with approval of Department) to Society
 - Previous grant of £12,000 increased this year to £30,000.
 - (iii) Other Support from the Department
 - Funding in 1988 (£15,000) from the National Lottery for counselling services has been provided to St. James Hospital where the National Haemophilia Unit is located.



Brian O Mahony, I H S AGM & Annual Conference 2018




1991: 4 Local Election Candidates

■ Four Friends of the Society brought the tragedy of its HIV-infected members to Dublin's doorsteps when they stood in the June 1991 local election.

Their campaign was in protest at the Government's failure to offer adequate compensation despite persistent lobbying by the society for an out-of-court settlement of £15.5 million.

The four candidates were: Michael Kirwan, the father of a member, in Lucan/Palmerstown; Marie



Michael Kirwan



Marie O'Connor



Joe Dowling



Gay McEvoy

O'Connor, a carer and committed friend of the society, in Clondalkin; Joe Dowling, a HIV-positive member, in Artane; and Gay McEvoy, the widow of a society member, who stood in Cabra.

Their campaign message was simple: 'Irish people with haemophilia suffering from HIV and AIDS are being ignored by the

Government – support the demand for a just settlement.'

According to Kirwan, about a third of the people he canvassed did not know what haemophilia was.

He says: 'It got to the stage that we had to bring the human aspect of the situation to peoples' doorsteps. The response we got was quite good. We spent a

lot of time explaining the situation to people and that in itself was very worthwhile.' About three weeks before polling day – in which none of the

candidates were elected – the Government made an offer of £8 million which the society accepted.

'They spiked our guns,' says Kirwan who says with a laugh that he has since lost his political ambition. Kirwan polled respectably with 210 votes. 'I didn't go along to the count, I heard it at work on the radio and I got an awful lot of flak.'



Rory O'Hanlon & Brian O'Mahony on Today Tonight

1992 - 1996

Death Toll from HIV

1992	3
1993	13
1994	10
1995	6
1996	3
Total	35
Total 1986-1996	56



Critical Illness Service



**Rosemary
Daly**



**Margaret
King**



**Margaret
Dunne**





**Teresa
Mulvey**

1990-1995 : A new Virus emerges: Hepatitis C



- Hepatitis C virus characterised in 1989- first discussed at Society AGM in 1990
- 1990-1994: worked on getting members tested and access to treatment
- 1994 -1995: discussions with DOH on compensation
- 1996 - Hepatitis C compensation tribunal
 - Health Amendment act
- Assistance provided to members going through tribunal including sourcing of legal team and expert witnesses



I.H.S. Office: 1991 - Eustace Street



Brian O Mahony, I H S AGM & Annual Conference 2018


1993




- Celebrated 25th Anniversary of I H S
- Videotape on 25th produced
- President Robinson attended AGM



1996 WFH World Congress





- WFH Congress in Dublin with record attendance and profit for IHS
- Profit used toward purchase of HQ in 2007
- New Blood Product policy: Aspiration – recombinant for all








1997 – 2001 Tribunals of Inquiry

- 1997: Finlay Tribunal into BTSB- fails to deal with Society issues
- Society withdraws and demands new inquiry focused on Haemophilia
- Terms of reference agreed after 27 months
- Lindsay Tribunal sat for 196 days from Sept 1999 to Nov 2001
- Report issued in 2002
- **Recommendations for the future and work by Society on these crucial**



2002 Compensation Issues

- **New Compensation scheme in 2002:**
 - Fair and Equitable
 - Further compensation for HIV
 - Recognition of spouses, parents, carers
 - Proper compensation for families of those who had died



Improving access to care; During Tribunal Negotiations




- 1997 - Prophylaxis for all Children
- 1998 - Moved to new HQ in Smithfield:
 - near Lindsay Tribunal building
- 1999 - Recombinant Products for All
- 2001- new National Centre: NCHCD



Tribunal Recommendations used to set up New Decision Making Bodies



- 2002- Haemophilia Product selection and Monitoring Advisory Board (HPSMAB)
 - formal role for Society in selection of Factor concentrates
- National Haemophilia Council (NHC)
 - Statutory Body in 2004
- Formal role for I H S in recommending policy and Priorities



SI No. 451 of 2004
NATIONAL HAEMOPHILIA COUNCIL (ESTABLISHMENT) ORDER 2004

Statutory instrument

I, Micheál Martin, Minister for Health and Children, (herein referred to as "the Minister") in exercise of the powers conferred on me by Section 3 of the Health (Corporate Bodies) Act, 1961 (No. 27 of 1961) as amended by Section 22 of the Health (Amendment) (No. 3) Act, 1996 (No. 32 of 1996) and adapted by the Health (Alteration of Name of Department and Title of Minister) Order 1997 (S.I. No. 308 of 1997) hereby order as follows:

1. This Order may be cited as the National Haemophilia Council (Establishment) Order 2004.
2. In this Order:
 - "Chairperson" means the Chairperson for the time being of the Council;
 - "Council" means the National Haemophilia Council established by this Order;
 - "Eastern Regional Health Authority" means the authority established under section 7 of the Health (Eastern Regional Health Authority), Act, 1999;
 - "haemophilia" means the following disorders: inhibitors to factors VIII and IX, inherited deficiencies of factors I, II, V, VII, VIII, IX, X, XI, XIII and Von Willebrands Disease;
 - "health board" means-
 - (a) A board established under section 4 of the Health Act, 1970, or
 - (b) An Area Health Board established by section 14 of the Health (Eastern Regional Health Authority) Act, 1999;
 - "Minister" means the Minister for Health and Children;
 - "officer" means an employee of the Council, unless the context otherwise requires.
3. (1) A body to be known as the National Haemophilia Council is hereby established to perform the functions conferred upon it by this Order.
(2) The Council shall be a body corporate with perpetual succession and a seal and with power to sue and be sued in its corporate name and to hold land.




National Haemophilia Council

- Hepatitis C lookback in 2005
- Managed vCJD Risk Assessment in 2004
- Commissioned external Audits of treatment centre's since 2006
- Recommendations on prioritisation of resources between centres and nationally



2006-2010

- Insurance scheme for members with HIV/Hepatitis C:
 - Life/Mortgage/travel insurance
- EHC Conference Dublin
- New haemophilia centre opened in Cork
- Increasing number of children and teenagers programmes and activities





KIDLINK PROGRAMME

40th Anniversary AGM 2008

**The Park Plaza Hotel,
Tyrrelstown, Dublin 15**

29th February, 1st & 2nd March

DVD COVER 11th Sept 07, step new 11/09/2007 09:46 Page 1

PERSONAL STORIES OF LIVING WITH HAEMOPHILIA



Gerard O'Reilly was born in 1959 and raised in rural Ireland in a town called Freshford, Co. Kilkenny. Gerard tells his story of living with haemophilia in the 1960's and 1970's.



Michael Longhane lives in rural Ireland. He gives an account of the differing experiences of his son Vincent and grandson Paul who were both born with haemophilia in different decades.



Kevin Biddart is father to a 9 year old Conor who has haemophilia B. Kevin tells his story about living with haemophilia.



Declan Noone is 25 years of age and has severe haemophilia A. Declan gives an outline of living with haemophilia during the 1980's and 1990's.



Mary Hasey is the mother of 2 boys, Sean aged 13 and Daniel aged 9, both have severe haemophilia A. Mary tells her story.

What is Haemophilia? Haemophilia is a lifelong bleeding disorder affecting mostly males which if left untreated can cause severe deformity, crippling and even death. Effective treatment has only become gradually available in the last 40 years in Ireland. These are the personal stories of 5 people and how their lives have been impacted by haemophilia over the last 4 decades. It is both touching and insightful, and chronicles how life has changed for the better through advancements in treatment and the tenacity of those demanding the best treatment and facilities.

Contact Us:
First Floor
Cathedral Court
New Street
Dublin 8

Tel: 01 6579900
Fax: 01 6579901

Email: info@haemophilia.ie
Website: www.haemophilia.ie

An IHS Production
Produced by: Shay Farnell, Margaret Dunne & Brian O'Mahony

Irish Haemophilia Society

www.haemophilia.ie

haemophilia through the generations

Personal Stories of Living with Haemophilia



IRISH HAEMOPHILIA SOCIETY

2007: Finally...our own HQ



XX1 - V1
Irish Examiner
Friday 15.06.2007

NEWS 9

Haemophilia headquarters after 40 years

by Evelyn Ring

AFTER almost 40 years the Irish Haemophilia Society that championed the rights of haemophiliacs caught up in the blood contamination scandal has permanent headquarters.

President Mary McAleese, who opened the new offices in Dublin's Liberties yesterday, said it was a "landmark day" for both members and supporters of the society.

The day was more than tinged with sadness, however, because of lives lost and damaged by infected blood products used to treat people with haemophilia between the mid-1970s and 1991.

Infected blood products were responsible for infection since haemophiliacs with HIV had 220 with hepatitis C. It of have been 91 deaths.

The society plans blood permanent memorial people who have died we new offices.

President McAleese are those who had died wod or be honoured by the worked in the new relief ters.

"It is through the v now ried out here that a n than ter future will be crpast. our citizens with haeto be and related bleeding das in she said.

The society plays ational tant role in shaping haNHC) ia treatment policy a who might have received HIV or hepatitis C before 1992 to come forward to be tested for the viruses.

Mr O'Mahony said one person who had contracted hepatitis C prior to 1991, but had not been diagnosed or identified, came forward.

There are about 450 people with haemophilia in Ireland and more than a 180 regularly attend the society's annual meetings.

The society also has a very active children's and teenagers' programme for up to 100 of its younger members.



President Mary McAleese with Luz Maria Heaney and Conor Birkett at the opening of the Irish Haemophilia Society office yesterday.

- www.haemophilia-society.ie
- www.nationalhaemophilia-council.ie



2010-2013



- 15 year mortgage paid off in 6 years
- Apartments purchased for members use near St. James
- Law to change contract holder for Haemophilia medications
- Clinical trials start for Extended half life (EHL) factors





2012-2016: Hepatitis C

- Successful advocacy for access to Hepatitis C treatments
- Strong support provided to members on treatment
- Commitment received from Minister for prioritised access
- 2016: Hepatitis C effectively eradicated in haemophilia in Ireland.



Haemophiliacs seek access to new treatment

Group says 350 Hepatitis C patients urgently need new therapies to stay alive



The Irish Haemophilia Society has called for early access to new treatments for 350 seriously ill patients with Hepatitis C. Photograph: Andrew Matthews/PA Wire

Paul Cullen Topics: News Health Brian O Mahony Deirdre Mulholland Paul Cullen Suzanne Norris Department of Health

Mon, Sep 15, 2014, 13:19 Recommend 13 Tweet 14 8+1

The Irish Haemophilia Society has called for early access to new treatments for 350 seriously ill patients with Hepatitis C.

It says this group cannot medically tolerate the current Interferon-based treatments Tuesday 16 September 2014

News

New 'life saving' drugs for Hep C sufferers

Mark O'Regan PUBLISHED 16/09/2014 | 02:30 COMMENTS SHARE



Brian O'Mahony, Irish Haemophilia Society Chief Executive.

New "life saving" drugs which cost €45,000 per patient, and have a 95pc success rate, should be made available to Hepatitis C sufferers with only months to live.

The Irish Haemophilia Society is calling for an "immediate positive decision" on the drugs given as a once-off treatment.

It is estimated 350 patients require these special treatments because they cannot tolerate the existing treatment care system. In some cases this is causing severe liver damage, which can be life-threatening. A total of 12,365 people in Ireland need Hepatitis C treatment

Brian O'Mahony, the society's chief executive, said new licensed drugs on the market

RTÉ News

HOME IRELAND WORLD BUSINESS SPORT PLAYER

PROGRAMMES

Ireland > Health

Call for early access to Hepatitis C treatments

7 f 13 g+ 1

Monday 15 September 2014 21:41

More than 260 people with haemophilia were infected with the virus from contaminated blood products

The Irish Haemophilia Society has called for 350 seriously-ill people with the Hepatitis C virus to be given early access to new treatments that could save their lives.

Irish Independent Tuesday 16 September 2014

ate the current Interferon treatment, due to risk of death.

who need Hepatitis C treatment, 350 have been in need of urgent treatment.

New 'life saving' drugs for Hep C sufferers

Mark O'Regan

NEW "life saving" drugs which cost €45,000 per patient, and have a 95pc success rate, should be made available to Hepatitis C sufferers with only months to live.

The Irish Haemophilia Society is calling for an "immediate positive decision" on the drugs given as a once-off treatment.

It is estimated 350 patients require these special treatments because they cannot tolerate the existing treatment care system. In some cases this is causing severe liver damage, which can be life-threatening. A total of 12,365 people in Ireland need Hepatitis C treatment

Brian O'Mahony, the society's chief executive, said new licensed drugs on the market should be provided to the most severe sufferers "as a matter of urgency."

"The sickest 3pc are in great risk of death within 12 months without the treatment," he told the *Irish Independent*.

Hep C patients 'will die without new therapies'

HUNDREDS of hepatitis C sufferers face liver failure or death within 12 months – unless they get access to new therapies.

The CEO of the Irish Haemophilia Society said the clock was ticking 'very loudly' for 350 people who cannot tolerate their Interferon-based drugs.

Brian O'Mahony has now called on Health Minister Leo Varadkar and the HSE to provide early access to the new treatments, which cost around €45,000 and are administered as a one-off.

There are 12,365 patients here who need hepatitis C treatment, 350 of whom need immediate care.

"What we're worried about at the moment is the 350 people who urgently need treatment," said Mr O'Mahony. "Otherwise they face a very significant chance of death or liver failure or the requirement of liver transplant in the next year. They can't wait."

Interferon-based therapies can cause severe liver damage and can increase the risk of death if a patient uses them for a long period of time.

Mr O'Mahony said the State can save €10.5million if the decision to provide treatment is taken before the end of October when one of the two new drugs is licensed.

Patients with Hepatitis C 'should have immediate access to potential life-saving therapies' - Irish Haemophilia Society


Mark O'Regan Twitter

Email

Published 15/09/2014 | 11:58




Brian O Mahony, I H S AGM & Annual Conference 2018



Call for early access to Hepatitis C treatments

Monday 15 September 2014 21:41



The Irish Haemophilia Society has called for 350 seriously-ill people with the Hepatitis C virus to be given early access to new treatments that could save their lives.

It said this group can not medically tolerate the current Interferon treatment, due to severe liver damage that increases their risk of death.

The society said of the 12,365 patients who need Hepatitis C treatment, 350 have been identified by specialist hepatologists to be in need of urgent treatment.



01/07/2015

Dear Mr O'Mahony

I am writing to you regarding the introduction in Ireland of new innovative Direct Acting Anti-viral medicines for the treatment of hepatitis C. As you are probably aware, these drugs significantly alter the prognosis for people infected with hepatitis C. In 2014, in order to ensure the most appropriate management of access to these costly new drugs, an Expert Advisory Group was established by my Department. The findings of the Group were presented in an expert report entitled "*A Public Health Plan for the Pharmaceutical Treatment of Hepatitis C*".

This Report sets out the basis on which a multi-annual approach to the provision of treatment for hepatitis C could be taken. This multi-annual approach has recently been approved by the Government. The key elements of the plan include the following:

- Access to these new innovative drugs will be based on internationally-accepted clinical prioritisation criteria.
- The HSE will establish a new National Treatment Programme for Hepatitis C which will be responsible for implementing the clinical prioritisation criteria and for making further revisions and extensions to the clinical criteria as the programme is rolled-out in the coming years.

an be pleased to inform you that the Government is committed to ensuring that, at the latest, by the end of 2017, all persons who contracted hepatitis C through the administration of blood and blood products in the State will have access to these new drugs, if prescribed for them by their treating clinician. It is important to note that in practice I expect that most, if not all, of these patients will be afforded access to these drugs in the course of 2015 and in 2016. Indeed it would be the Government's intention that, if possible, the target date of 2017 be improved upon such that all State-infected patients who require treatment would have received it by the end of 2015. In addition, the Government is also considering prioritisation of the funding to address the National Treatment Programme for Hepatitis C which the HSE is currently putting on a firm footing and which involves the relevant national experts in identifying the patients concerned and the order in which they should be treated.



Hepatitis C in Irish haemophilia population 'eradicated'

Updated / Dec. 22, 2016 10:59



Over a 20-year period, 240 people with haemophilia in Ireland were infected with Hepatitis C by blood products



[Home](#) > [Press Release](#) > Harris hails effective eradication of Hepatitis C in haemophilia patients a great achievement for Ireland

Press Release

Harris hails effective eradication of Hepatitis C in haemophilia patients a great achievement for Ireland


22.12.2016



Minister for Health Simon Harris is delighted that haemophilia patients being treated under the HSE National Hepatitis C Treatment Programme have had excellent success rates. Haemophilia patients infected with Hepatitis C from blood products have been offered treatment under the Programme, the majority of whom have now completed treatment.

Haemophilia Product Selection and Monitoring Advisory Board 2002- 2018



- **Completed 17 National tenders ;**
 - Recombinant FVIII
 - Recombinant FIX
 - Plasma derived FVIII for von Willebrands
 - FX Concentrate
- 
- Primary selection Criteria: **Safety, Efficacy, Quality, Supply, Cost**
 - FVIII use of 13 Million IU for 2002 increased to 44 Million IU for 2015
 - FIX per capita use at 2.36 IU highest in world
 - “Savings” over old system of €132 Million from 2002 -2014

Haemophilia Product Selection and Monitoring Advisory Board 2002- 2018



- Lower costs re-invested in Haemophilia care
- FVIII and FIX use in 2017 highest in world:
 - Council of Europe recommended minimum FVIII use 4 IU/pc
 - Global average use, high income countries: 6.16 IU/capita
 - Ireland FVIII use 11 IU/capita.

Council of Europe recommended minimum: 0.5 IU/capita
Ireland FIX use 2.52 IU/capita

- New comprehensive care centre in Cork, 2010
- New in-patient H and H unit Dublin, 2013
- New National Coagulation centre, St. James's, 2017



National Coagulation Centre 2017



Brian O Mahony, IHS AGM & Annual Conference 2018



Collaborative work on HPSMAB

- We use the safest most efficacious treatments for all
- Significantly lower cost than EU- 70% lower
- Highest Factor use globally
- Significant investment in Haemophilia infrastructure- even during recession and bailout
- More innovative participation in clinical trials
- First country in world to treat all people with Extended half Life FVIII and FIX




Figure C4a. Mean per capita factor VIII use in 2016 – regional and GNI comparisons of IU/total population: Europe



Economic category based on The World Bank Group 2016 rankings for "Gross national income (GNI) per capita, Atlas method (current US\$)". (GNI in US dollars: D lower income, \$0-\$1,005; C lower middle income, \$1,006 - \$3,955; B upper middle income, \$3,956 - \$12,235 and A high income, \$12,235 or more.) (Regions based on WHO regions.)

PLEASE NOTE: The X axis showing the number of IU/capita is different in each graph. The orange line indicates 1 IU per capita of factor VIII. The WFH has established that one international unit (IU) of FVIII clotting factor concentrate per capita should be the target minimum for countries wishing to achieve survival for the hemophilia population. Higher levels would be required to preserve joint function or achieve a quality of life equivalent to an individual without hemophilia. Please note the orange line does not apply to factor IX. Only countries that completed the 2016 questionnaire are included in these charts.

Figure C4b. Mean per capita factor IX use in 2016 – regional and GNI comparisons of IU/total population: Europe




Economic category based on The World Bank Group 2016 rankings for "Gross national income (GNI) per capita, Atlas method (current US\$)". (GNI in US dollars: D lower income, \$0-\$1,005; C lower middle income, \$1,006 - \$3,955; B upper middle income, \$3,956 - \$12,235 and A high income, \$12,235 or more.) (Regions based on WHO regions.)

PLEASE NOTE: The X axis showing the number of IU/capita is different in each graph. Only countries that completed the 2016 questionnaire are included in these charts.



FIX trough levels 2017: Switch to EHL FIX



FVIII Tender Ireland 2017: First country to switch entirely to EHL FVIII and FIX




CRITERIA		
SAFETY	Human Albumin in Culture Medium	5 - 15
	Additional Human or Animal Protein (e.g. monoclonal antibodies)	3 - 7
	Viral Inactivation	10 - 20
	Inhibitors	20 - 40
	Prion Removal	3 - 7
	Other Adverse Events	5 - 15
	Other Safety Concerns	10 - 20
	Total for Safety	56 - 124
EFFICACY	Pk (Half Life / Time to trough of 3%/ AUC)	20 - 60
	Data in relation to ability to infuse prophylactically twice per week	5 - 15
	Recovery	10 - 20
	Clinical Response (adult/paediatric)	10 - 20
	Total for Efficacy	45 - 115

QUALITY	Stability	3 - 10
	Volume of Administration	3 - 10
	Instructions for Use & Handling	3 - 5
	Ease of Administration	3 - 5
	Application of Unique Bar-Code	3 - 5
	Total for Quality	15 - 35
SECURITY OF SUPPLY & AVAILABILITY	Number of Manufacturing Plants	5 - 10
	Security of Supply	10 - 20
	Supply/ Availability	15 - 30
Total Scores Awarded: Phase 1		131 - 304
Phase 2		
COST	25 - 75	
Rebate 4%	10 - 20	
Total Scores Awarded:		166 - 399



Innovative and early use of Technology

- Electronic patient record system
- App to report home treatment now in use for 11 years
- HSE funded Lighthouse project being used to develop patient portal
- Return more control to PWH over their condition





Ireland at forefront with Clinical Trials

- Children participated in clinical trials on EHL FVIII and FIX
- Clinical trial for Emicizumab SC therapy
- Clinical trial on EHL for Immune Tolerance

Clinical trials due to commence this year:

- Fitusiran SC therapy
- Gene Therapy for FIX



Research and Development projects

- Outcomes research on treatment:
 - PROBE, Hemo-Qol, qualitative
- IPATH Research project to answer fundamental biological questions on haemophilia
- Development programme with Vietnam Haemophilia Society:
 - improved access to treatment and care
 - micro employment
 - home adaptation



Research- Unanswered questions



1. Why is factor concentrate cleared rapidly from the blood in some patients and slowly in other patients ?
2. Why do some patients with severe haemophilia demonstrate lots of bleeding complications whilst other patients bleed rarely ?
3. Why do some young boys with severe haemophilia develop joint degeneration after only a few joint bleeds whereas other patients have well preserved joints despite lots of joint bleeding?
4. Why do some patients develop inhibitors and others do not ?



€4m haemophilia treatment study to be launched

Updated / Monday, 4 Dec 2017 11:39



Study is open to children and adults with moderate to severe haemophilia

A €4 million four-year long study that to develop personalised treatments people with haemophilia will be launched.

iPATH
Irish Personalised Approach to the Treatment of Haemophilia

Treating the person, not the disease

About the iPATH study

- The Irish Personalised Approach to the Treatment of Haemophilia (iPATH) study is a partnership between the Royal College of Surgeons in Ireland (RCSI), Science Foundation Ireland (SFI), SHire and the Irish Haemophilia Society.
- The study aims to generate insights about the difference in patient experience of the underlying factor deficiency.
- Using a database of more than 10 years of outcomes, together with pharmacokinetic data and whole genome sequencing, iPATH will help define how genetics and other biological markers may impact patients' responses to prophylaxis treatment.
- iPATH is a four-year study initiated in 2017 and taking place in Ireland.

iPATH is designed to address several unanswered questions in haemophilia

- Why is factor concentrate cleared rapidly in some patients and slowly in others?
- Why do some patients with severe haemophilia demonstrate lots of bleeding complications whilst other patients bleed rarely?
- Why do some young boys with severe haemophilia develop joint degeneration after only a few joint bleeds whereas others have well-preserved joints despite lots of bleeding?
- Why do some patients develop inhibitors and others do not?

The iPATH study hopes to

- TAILOR treatment to patient needs
- IMPACT the global delivery of haemophilia prophylaxis
- BE A MODEL for future studies in other chronic diseases and in other prophylaxes

Facts about Haemophilia

- Haemophilia is an inherited bleeding disorder caused by the lack of a blood clotting protein (known as factor). This results in prolonged bleeding that is difficult to stop unless the condition is recognised and treated.
- Without treatment, severe haemophilia can cause serious internal or life-threatening bleeding. Bleeding can occur without any injury spontaneously into any part of the body although typically the joints (elbows, knees and ankles) are affected.
- There is no cure for haemophilia, but it can be treated by replacing the missing blood clotting factor.
- The worldwide incidence of haemophilia is estimated to be greater than 400,000.
- Approximately 800 people in Ireland are affected.
- Approximately 75% of people with haemophilia around the world still receive inadequate treatment or have no access to treatment.

REFERENCES

1. Irish Haemophilia Society (IHS) 2016. Haemophilia in Ireland. Available at: www.ihss.ie [accessed 10 Dec 2017].

2. Irish Haemophilia Society (IHS) 2016. Haemophilia in Ireland. Available at: www.ihss.ie [accessed 10 Dec 2017].

3. Irish Haemophilia Society (IHS) 2016. Haemophilia in Ireland. Available at: www.ihss.ie [accessed 10 Dec 2017].

4. Irish Haemophilia Society (IHS) 2016. Haemophilia in Ireland. Available at: www.ihss.ie [accessed 10 Dec 2017].

5. Irish Haemophilia Society (IHS) 2016. Haemophilia in Ireland. Available at: www.ihss.ie [accessed 10 Dec 2017].

6. Irish Haemophilia Society (IHS) 2016. Haemophilia in Ireland. Available at: www.ihss.ie [accessed 10 Dec 2017].

Global Contribution

Twinning programmes with :


- Hungary (1994-1997)
- Belarus (1997-1999)
- Greece (2000-2003)
- Bosnia and Herzegovina (2004- 2008)
- Vietnam (2010- Present)
- Contribution to WFH GAP programme






Strategic Planning for Society

Strategic plan 2011-2014



Strategic Plan 2015-2018





Conferences



Brian O Mahony, IHS AGM & Annual Conference 2018



Education / Activities for Kids and Teens



Publications



Brian O Mahony, I H S AGM & Annual Conference 2018

1.H.S. 26th June 2015

[View this email in your browser](#)



Report from the Parents Conference 2015

This year's Parents Conference took place in the Sheraton Hotel in Athlone over the weekend of 19th to 21st June. We had 71 adults and 78 children booked in for the weekend, along with 36 volunteers, staff and speakers. We left the office early on Friday morning to make our way to Athlone to set up. With everything organised, we were ready for registration at 6pm. As members registered with their children it was obvious how excited the children were to meet up with their friends again, and they were all so looking forward to the weekend.




The Society at a Glance

672 Facebook Followers	49 Planned giving Contributors	59 IHS Volunteers	4733 Website Hits
------------------------	--------------------------------	-------------------	-------------------

Edition: April 2015

[haemophilia.ie](#)

Website & Social Media





Co-Designed service

Clinicians and Irish Haemophilia Society work together on co-design of service

- Statutory National Haemophilia Council oversees service
- Haemophilia Product Selection New technology introduced with patient participation
- Research projects jointly conducted
- Joint training and education initiatives

Severe Bleeding Disorder Alert Card



Brian O Mahony, I H S AGM & Annual Conference 2018





“The farther backward you can look, the farther forward you are likely to see.” Winston Churchill



Brian O Mahony, I H S AGM & Annual Conference 2018





50th Anniversary activities

- Movie on history of Society
- Digital archive
- Chronology and photo history
- Graffiti Art project
- World Haemophilia Day events
- Gala dinner
- 10 events/conferences

EXTRACTS FROM MINUTES OF PRELIMINARY, INFORMAL MEETING HELD ON	
MAY 22, 1968	
IN THE HIBERNIAN HOTEL, DUBLIN	
FOR THE PURPOSE OF CONSIDERING THE INAUGURATION OF A SOCIETY FOR HAEMOPHILIACS IN IRELAND.	
Mr. Sean Hanratty	said that prophylactic treatment could change the whole position. He felt that the Department must be approached through a formal association, and recommended that such an association be formed.
Dr. Temperley	felt that a centre is very important, but it would not be practical or financially feasible to have many. He thought it might be possible for some people to move nearer to the centre. He said that an



50th Anniversary: Conferences

- AGM/Annual conference
- Members Conference
- Ageing
- Carriers
- von Willebrand's
- Haemophilia B
- Mild Haemophilia
- Father and Son event
- Mother and Daughter event
- Inhibitor summit



I H S Staff team



Brian O Mahony, I H S AGM & Annual Conference 2018


I H S Board



I.H.S. Volunteers



Brian O Mahony, I.H.S. AGM & Annual Conference 2018



ANIMAL PHYSIOLOG

A Peanut Factor for Hæmostasis in Hæmophilia

It is known that there are unpredictable apparent remissions of clinical symptoms enjoyed by hæmophiliacs; but these remissions have not been correlated with any influences such as time of year, food eaten, weather conditions, other diseases, or physical condition of the patient. The lack of



Brian O Mahony, I H S AGM & Annual Conference 2018



Where are we now...

- Strong sense of community maintained through last 50 years
- Personal empathy, commitment by all allied to strong and forward looking strategic goals

That which does not destroy you will make you stronger

Nietzsche



The Future

- Better treatment, more options: better EHL, SC, Gene Therapy
- Better options for inhibitors, VWD, rare bleeding disorders
- Reduced treatment burden and improved quality of life
- **60th Anniversary:** young men will tell disbelieving children how they used to infuse intravenously every week
 - : newly diagnosed children may receive 1 treatment with Gene Therapy
- Comprehensive care centres will survive and flourish



The Future- will we need the Society

YES

- Gene defect remains- individuals and families will always need support
- Never assume resources will be available for best treatment- continued advocacy, work, collection of outcome data
- Promotion of haemophilia as a career to medical students
- Maintain the community of belonging, of empathy, of support, of innovation



*“The past is not dead.
It’s not even past”* William Faulkner